[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100343711":3},{"organization":4,"outcomesModule":7,"designInfo":13,"detailedDescription":11,"studyPopulation":11,"armGroups":21,"interventions":38,"overallOfficials":11,"centralContacts":52,"locations":58,"responsibleParty":78,"collaborators":11,"id":80,"slug":11,"hasResults":81,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":11,"eligibilityCriteria":85,"healthyVolunteers":81,"sex":86,"minAge":87,"maxAge":88,"enrollmentInfo":89,"targetDuration":11,"studyType":92,"phases":93,"briefSummary":95,"conditions":96,"keywords":11,"overallStatus":60,"whyStopped":11,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":107},{"fullName":5,"class":6},"Shinshu University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":11,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Assessment of bone mineral density in osteoporosis patients treated by SERM plus ELD, Bisphosphonate plus ELD, or ELD alone",null,"Change from Baseline Values of bone mineral density at 2 years in each group",{"allocation":14,"interventionModel":15,"interventionModelDescription":11,"primaryPurpose":16,"observationalModel":11,"timePerspective":11,"maskingInfo":17},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":18,"maskingDescription":11,"whoMasked":19},"SINGLE",[20],"PARTICIPANT",[22,30,34],{"label":23,"type":24,"description":25,"interventionNames":26},"SERM plus ELD","ACTIVE_COMPARATOR","To examine the effects of SERM plus ELD in osteoporosis patients",[27,28,29],"Drug: SERM \"Viviant®Tablet 20mg\" and ELD \"Edirol®Tablet 0.75ug\"","Drug: Bisphosphonates and ELD \"Edirol®Tablet 0.75ug\"","Drug: ELD \"Edirol®Tablet 0.75ug\"",{"label":31,"type":24,"description":32,"interventionNames":33},"BP plus ELD","To examine the effects of BP plus ELD in osteoporosis patients",[27,28,29],{"label":35,"type":24,"description":36,"interventionNames":37},"ELD alone","To examine the effects of ELD alone in osteoporosis patients",[27,28,29],[39,44,48],{"type":40,"name":41,"description":42,"armGroupLabels":43,"otherNames":11},"DRUG","SERM \"Viviant®Tablet 20mg\" and ELD \"Edirol®Tablet 0.75ug\"","To examine the effects of SERM and ELD in osteoporosis patients",[31,35,23],{"type":40,"name":45,"description":46,"armGroupLabels":47,"otherNames":11},"Bisphosphonates and ELD \"Edirol®Tablet 0.75ug\"","To examine the effects of BP and ELD in osteoporosis patients",[31,35,23],{"type":40,"name":49,"description":50,"armGroupLabels":51,"otherNames":11},"ELD \"Edirol®Tablet 0.75ug\"","To examine the effects of ELD in osteoporosis patients",[31,35,23],[53],{"name":54,"role":55,"phone":56,"phoneExt":11,"email":57},"Yukio Nakamura","CONTACT","+81263372576","yxn14@aol.jp",[59],{"facility":54,"status":60,"city":61,"state":62,"zip":63,"country":64,"countryCode":65,"cosmosGeoPoint":66,"geoPoint":71,"contacts":72},"RECRUITING","Matsumoto","Nagano","3908621","Japan","JP",{"type":67,"coordinates":68},"Point",[69,70],137.96667,36.23333,{"lat":70,"lon":69},[73,76],{"name":74,"role":55,"phone":75,"phoneExt":11,"email":57},"Yukio Nakamura, MD, PhD","+81-263-37-2659",{"name":74,"role":77,"phone":11,"phoneExt":11,"email":11},"PRINCIPAL_INVESTIGATOR",{"type":77,"investigatorFullName":54,"investigatorTitle":79,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"Lecturer at Shinshu University School of Medicine","100343711",false,"NCT03755193","Examination of Efficacy and Safety of Other Anti-Resorption Drugs After 2-year-Denosumab Therapy in Japanese Osteoporosis Patients","Examination of Efficacy and Safety of SERM or Bisphosphonates After 2-year-Denosumab Therapy in Japanese Osteoporosis Patients","Inclusion Criteria:\n\n* osteoporosis patients\n\nExclusion Criteria:\n\n* not osteoporosis patients who are allergic to the drugs, refused to do this research, or who are pregnant","ALL","20 Years","120 Years",{"count":90,"type":91},90,"ESTIMATED","INTERVENTIONAL",[94],"PHASE2","The aim of this study is to examine the efficacy and adverse events in the following 3 groups in Japanese osteoporosis patients after 2-year-denosumab therapy:\n\nSERM and eldecalcitol treatment for 24 months Bisphosphonates and eldecalcitol treatment for 24 months Eldecalcitol treatment for 24 months",[97],"Osteoporosis","2021-09-20",{"date":100,"type":101},"2021-09-21","ACTUAL",{"date":103,"type":101},"2018-11-24",{"date":105,"type":91},"2026-11-23",{"name":5,"class":6},1]